Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.

Clinical variables associated with ecotropic viral integration site 1 (EVI1) translocations were evaluated in 42 consecutive chronic myeloid leukemia (CML) patients in myeloid blast crisis (MBC). Translocations were confirmed with fluorescence in situ hybridization, and Western blot analysis demonstrated EVI1 expression. Translocations of EVI1 were present in 3 of 24 (12%) patients whose disease evolved MBC before tyrosine kinase inhibitor (TKI) exposure, and 7 of 18 (39%) patients who had received one or more TKIs. Univariate analysis showed that prior TKI therapy was the only clinical variable that was significantly associated with EVI1 translocation (P = 0.047). TKI-resistant BCR-ABL1 mutations were present in 71% of MBC patients with EVI1 translocations at the time of disease progression. These observations suggest that EVI1 overexpression collaborates with BCR-ABL1 in the evolution of TKI-resistant MBC. Inhibition of c-ABL kinase-mediated DNA double-strand repair by TKIs may predispose to EVI1 translocation in this setting.

[1]  R. Wieser.  The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. , 2007, Gene.

[2]  R. McGilvray,et al.  Conservation and expression of a novel alternatively spliced Evi1 exon. , 2006, Gene.

[3]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[4]  A. Melnick,et al.  Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. , 2011, Blood.

[5]  R. Ren,et al.  Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice , 2004, Oncogene.

[6]  H. Kurumizaka,et al.  c-ABL tyrosine kinase stabilizes RAD51 chromatin association. , 2009, Biochemical and biophysical research communications.

[7]  G. Nucifora,et al.  EVI1 Impairs myelopoiesis by deregulation of PU.1 function. , 2009, Cancer research.

[8]  D. Baltimore,et al.  Radiation-induced Assembly of Rad51 and Rad52 Recombination Complex Requires ATM and c-Abl* , 1999, The Journal of Biological Chemistry.

[9]  E. Thomas,et al.  Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia. , 1988, Bone marrow transplantation.

[10]  David D. Smith,et al.  An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies , 2007, British journal of haematology.

[11]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[12]  R. Weichselbaum,et al.  Determination of cell fate by c-Abl activation in the response to DNA damage , 1998, Oncogene.

[13]  G. Nucifora.  The EVI1 gene in myeloid leukemia , 1997, Leukemia.

[14]  G. Nucifora,et al.  Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Baccarani,et al.  Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.

[16]  H. Kantarjian,et al.  BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. , 2008, Blood.

[17]  R. Ren,et al.  Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia , 2001, Oncogene.

[18]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.